Welcome to our dedicated page for Mimedx Group news (Ticker: MDXG), a resource for investors and traders seeking the latest updates and insights on Mimedx Group stock.
MiMedx Group, Inc. develops and commercializes regenerative biomaterial products for wound care, burn and surgical applications. Its updates center on placental allografts and related advanced wound care technologies, including AMNIOFIX, CHORIOFIX and G4Derm Plus, as the company adds product configurations, distribution rights and clinical evidence for complex wound management.
Company news also covers operating results for the Wound and Surgical businesses, reimbursement-driven market conditions, cost-reduction actions, investor presentations, conference participation and capital actions such as share repurchase authorization.
MIMEDX Group (NASDAQ: MDXG) reported Q2 2024 financial results with net sales of $87 million, up 7% year-over-year. The company achieved GAAP net income of $18 million and Adjusted EBITDA of $20 million (23% of net sales). Key highlights include:
- Launch of HELIOGEN™, a Fibrillar Collagen Matrix and first xenograft product
- Commencement of Randomized Controlled Trial for EPIEFFECT®
- Publication in Nature – Scientific Reports on surgical applications of placental-based allografts
Despite strong results, MIMEDX faced commercial challenges due to competitive behavior in the skin substitute market. The company expects mid-to-high single-digit net sales growth for 2024, with long-term projections of low double-digit growth and Adjusted EBITDA margin above 20%.
MIMEDX Group, Inc. (Nasdaq: MDXG) announced the publication of a peer-reviewed study in Nature – Scientific Reports, focusing on how placental-based allografts may modulate scarring and fibrosis in surgical procedures. The study, titled "Human amniotic membrane modulates collagen production and deposition in vitro," is MIMEDX's first publication in this prestigious journal.
The research evaluated two configurations of PURION processed placental-based allografts: dehydrated human amnion chorion membrane (DHACM) and lyophilized human amnion chorion membrane (LHACM). Both demonstrated modulation of collagen production, deposition, and maturation, supporting the hypothesis that amniotic membranes may interrupt pathological fibrosis and restore tissue homeostasis.
This study adds to MIMEDX's growing body of evidence and expands the understanding of their allografts' regulatory capabilities in the fibrotic process, potentially leading to improved patient outcomes in procedures where pathological fibrosis results in detrimental scarring and dysfunctional tissue.
MIMEDX Group, Inc. (Nasdaq: MDXG) has announced that it will release its second quarter 2024 operating and financial results on Wednesday, July 31, 2024, after the market closes. The company's senior management team will host a webcast and conference call to discuss the results at 4:30 p.m. Eastern Time on the same day.
Investors can access the conference call using the following information:
- U.S. Investors: 877-407-6184
- International Investors: 201-389-0877
- Conference ID: 13747365
MIMEDX has appointed Kim Moller as Chief Commercial Officer (CCO), effective June 26, 2024. Moller, previously Senior Vice President of Sales since August 2020, will now oversee marketing and international commercial operations. CEO Joseph H. Capper praised Moller's leadership in transforming MIMEDX's commercial organization into a high-performing team. Moller brings nearly 30 years of sales leadership experience from reputable firms such as 3M, Acelity, and KCI. She holds a BSN from the University of Phoenix and an MBA from Colorado Christian University.
MiMedx Group (Nasdaq: MDXG) announced participation in two upcoming investor conferences. Senior management will attend the Craig-Hallum 21st Annual Institutional Investor Conference on May 29, 2024, at the Renaissance Minneapolis Hotel in Minneapolis, MN. They will also be present at the Northland Growth Conference 2024 on June 25, which will be held virtually. Investors can arrange meetings with senior management by contacting their respective Craig-Hallum or Northland representatives.
MiMedx Group, Inc. (Nasdaq: MDXG) announced first quarter 2024 results with net sales of $85 million, 18% growth year-over-year, GAAP net income of $9 million, adjusted EBITDA of $19 million, and other notable achievements like portfolio expansion and new directors.
Summary not available.
Summary not available.
Summary not available.
Summary not available.